LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) CEO Justin Schreiber sold 25,000 shares of the business's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $12.47, for a total value of $311,750.00. Following the sale, the chief executive officer now owns 2,525,721 shares in the company, valued at approximately $31,495,740.87. The trade was a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Justin Schreiber also recently made the following trade(s):
- On Thursday, May 1st, Justin Schreiber sold 21,995 shares of LifeMD stock. The shares were sold at an average price of $7.53, for a total transaction of $165,622.35.
- On Tuesday, April 29th, Justin Schreiber sold 50,000 shares of LifeMD stock. The stock was sold at an average price of $7.78, for a total value of $389,000.00.
LifeMD Price Performance
NASDAQ:LFMD traded up $0.73 during mid-day trading on Friday, reaching $12.81. The stock had a trading volume of 1,215,382 shares, compared to its average volume of 1,004,476. The stock has a market cap of $581.96 million, a P/E ratio of -20.02 and a beta of 2.42. The business's 50 day moving average is $7.97 and its 200 day moving average is $6.46. LifeMD, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $13.25.
LifeMD (NASDAQ:LFMD - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.05. The company had revenue of $65.70 million during the quarter, compared to analyst estimates of $62.47 million. Equities analysts expect that LifeMD, Inc. will post -0.56 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers grew its position in shares of LifeMD by 6.1% in the fourth quarter. Rhumbline Advisers now owns 48,689 shares of the company's stock valued at $241,000 after purchasing an additional 2,814 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in LifeMD by 4.8% during the 4th quarter. Los Angeles Capital Management LLC now owns 127,435 shares of the company's stock valued at $631,000 after purchasing an additional 5,850 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in LifeMD by 5.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 108,478 shares of the company's stock valued at $537,000 after buying an additional 6,034 shares during the last quarter. Raymond James Financial Inc. bought a new position in LifeMD in the 4th quarter worth approximately $473,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in LifeMD by 21.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 931,294 shares of the company's stock worth $4,610,000 after buying an additional 165,378 shares during the period. 35.52% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms have issued reports on LFMD. HC Wainwright reissued a "buy" rating and set a $14.00 price target on shares of LifeMD in a research report on Wednesday, April 30th. B. Riley raised shares of LifeMD to a "strong-buy" rating in a research report on Tuesday, March 11th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $15.00 target price on shares of LifeMD in a research report on Tuesday, March 11th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $11.00.
Check Out Our Latest Stock Analysis on LifeMD
About LifeMD
(
Get Free Report)
LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.
See Also
Before you consider LifeMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list.
While LifeMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
